ATRO vs CXT

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant deterioration in core profitability and operational metrics. Despite strong recent earnings surprises and impressive short-term price momentum (+344.9% over 1Y), the company is unprofitable on a net basis (Profit Margin: -0.37%, ROE: -1.73%) and carries a dangerously high Debt/Equity ratio of 3.48. Valuation multiples are stretched (Forward P/E: 30.32, P/B: 24.85) relative to peers and lack support from sustainable earnings or cash flow visibility. Insider selling and lack of dividend strength further undermine confidence in long-term value preservation.

CXT presents a dichotomy between strong top-line growth and deteriorating bottom-line performance. While the Piotroski F-Score of 6/9 indicates a stable financial foundation, the stock is trading at a significant premium to its Graham Number ($35.03) and Intrinsic Value ($17.50). Despite consistent earnings beats and robust revenue growth of 19.5%, the YoY earnings decline of 18% and a severe 31.5% price drop over the last six months suggest a loss of market confidence. The outlook remains neutral as the attractive forward P/E (9.52) is offset by bearish insider sentiment and a strong technical downtrend.